🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

455 results for “60” Clear

  1. CABOMETYX 40 mg film-coated tablets, CABOMETYX 60 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Fondazione Telethon ETS

    Non small-cell lung cancer

    phase 2 small molecule active

    1 trial

  2. CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Ipsen Pharma

    Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

    phase 2 small molecule active

    1 trial

  3. CAPECITABINE, CAPECITABINE, TRIPTORELIN, [177Lu]-NeoB solution for infusion, LEUPRORELIN, AAA503, GOSERELIN

    Novartis Ophthalmics Europe

    Breast Cancer

    phase 2 small molecule active

    1 trial

  4. CEP-701 60mg

    Teva Pharma GmbH

    Leukemia, Myeloid

    phase 2 small molecule completed

    1 trial

  5. CHF6001 DPI

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 2 small molecule active

    1 trial

  6. CPGJ602

    Sunshine Biopharma

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  7. CRB-601 monoclonal antibody

    Corbus Pharmaceuticals Holdings

    Solid Tumor

    phase 2 small molecule active

    1 trial

  8. CTI-1601

    Larimar Therapeutics

    Friedreich Ataxia

    phase 2 mab active

    4 trials

  9. CYCLIZINE , CALCIUM CARBONATE , Placebo for azd9550, CALCIUM CITRATE , CALCIUM GLUCONATE , Placebo for azd6234, Placebo for azd9550, AZD6234, GLUCOSE , GLUCAGON , ONDANSETRON

    AstraZeneca AB

    Investigating obesity or overweight condition correlated to many co-morbidities

    phase 2 small molecule active

    1 trial

  10. Cannabidiol (CBD) 600 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule completed

    1 trial

  11. Celgosivir

    60 DEGREES PHARMACEUTICALS, INC.

    Dengue Fever

    phase 2 small molecule terminated

    1 trial

  12. Cetuximab

    United Therapeutics Europe Ltd

    BRAF V600E Negative

    phase 2 mab active

    1 trial

  13. DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Empliciti 400 mg powder for concentrate for solution for infusion., Dexamethason CF 20 mg/ml, injectievloeistof, Dexamethasone 2mg Tablets, VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, Dexamethason 4 mg JENAPHARM®, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, CC-92480, CC-92480

    Celgene Europe Limited

    Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)

    phase 2 small molecule active

    1 trial

  14. DURVALUMAB , Ifinatamab Deruxtecan, MK-6070

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 small molecule active

    1 trial

  15. Dabogratinib (TYRA-300) 60mg

    Tyra Biosciences

    Low Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  16. Datopotamab deruxtecan

    AstraZeneca AB

    Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy

    phase 2 small molecule active

    1 trial

  17. ENCORAFENIB , CETUXIMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had received and responded to a BRAF inhibitor-based treatment.

    phase 2 small molecule active

    1 trial

  18. ENTR-601-44

    Entrada Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  19. ENTR-601-44, SODIUM CHLORIDE

    Entrada Therapeutics

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  20. ENTR-601-45

    Entrada Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  21. Encorafenib + Binimetinib

    Regeneron UK Limited

    Melanoma BRAF V600E/K Mutated

    phase 2 small molecule active

    1 trial

  22. First-line Chemotherapy With Temozolomide Alone for Non-enhancing Adult Brainstem Gliomas, With a Diffuse Subtype and Showing Clinical and/or Radiological Infiltrative Pattern of Progression (TEMOTRAD01)

    Pari Pharma GmbH

    Adults with non-contrast-enhancing diffuse brainstem gliomas with non-threatening infiltrative clinical and/or radiological progression, Adult brain stem gliomas

    phase 2 other active

    1 trial

  23. GADOTERIC ACID , PARACETAMOL , coramitug, CETIRIZINE , SODIUM CHLORIDE

    Novo Nordisk A/S

    Participants with transthyretin amyloid cardiomyopathy (ATTR CM)

    phase 2 small molecule active

    1 trial

  24. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources